This study is a sequential single blind randomized trial on 18-70 years age, new diagnosed cancer patients that should undergo antracyclin therapy. Written informed consent are obtained from all patients. Before initiation of chemotherapy, all patients undergo echocardiography by Vivid S5 and the images are stored for off line analysis. Left ventricular end diastole and end systole diameters are measured and LVEF is calculated by Simpson method. Evaluation for diastolic function is performed by mitral inflow evaluation: pulse doppler (E,A wave, E/A ratio, E wave deceleration time), pulmonary veins flow and tissue doppler of mitral valve annulus. E/e' ratio is calculated for determination of filling pressure. Patients are inserted randomly in control(no carvedilol)and intervention(carvedilol)groups. Age,sex and other variables are similar in two groups. In the intervention group, carvedilol is initiated at least 24 hours before first cycle of chemotherapy. Initial dose is 3.12mg BID( in patients with systolic blood pressure more than 90-100mmHg). Dose is gradually increased after one week. If systolic blood pressure is more than 90 mmHg , maximum dose is increased to 6.25mg BID. Patients in intervention group are evaluated for hypotension, bradycardia and etc. If hypotension occurs, carvedilol is decreased or stopped. If systolic blood pressure increased, it is again initiated. All patients receive chemotherapy according to protocol.One month later,cardiac Troponin I is measured. Then, in the terminal part of follow up, after 6months, patients undergo echocardiography that echocardiographer is blinded. Two groups are compared for change in left ventricular systolic and diastolic performance and Troponin levels.